Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy. - AlzForum Alzheimer Research Paper of the Week


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Papers of the Week

Annotation

	Morelli L, Llovera RE, Mathov I, Lue LF, Frangione B, Ghiso J, Castaño EM. Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J Biol Chem. 2004 Dec 31;279(53):56004-13. PubMed Abstract

	Comments on Paper and Primary News

	Primary News: IDE—Levels Up, But Activity Down, in Amyloid-Burdened Vasculature Comment by: Chris Exley
	Submitted 28 October 2004 \| Permalink	Posted 29 October 2004
	We already know that another candidate enzyme for the in vivo degradation of Aβ plasmin is inhibited by aluminium (Al) (Korchazhkina et al., 2002). Perhaps Al might also inhibit IDE? References: Korchazhkina et al. (2002) The degradation of Aβ25-35 by the serine protease plasmin is inhibited by aluminium. JAD 4, 357-367. Abstract View all comments by Chris Exley

Submit a Comment on this Paper

Cast your vote and/or make a comment on this paper.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password	Minimum of 8 characters
*Confirm Password
Stay signed in?

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.

REAGENTS/MATERIAL:

Antibodies used were: polyclonal anti-rat IDE BC2 (97-273 sequence); monoclonal anti-IDE antibody 1C1 and 3A2; monoclonal anti-IDE 9B12 (gift of Richard Roth); monoclonal CD31 (DAKO); monoclonal anti-laminin and monoclonal anti-a-actin (Sigma); rabbit polyclonal anti-neuronal specific enolase (NSE) (Santa Cruz Biotechnology); monoclonal anti-Ab 6E10 (Signet) and 3D6 (gift from Elan Pharmaceuticals) and monoclonal mouse IgG1 against the papilloma virus E2 protein (gift of Fernando Goldbaum).